JEAN FRANCOIS FORMELA
CIK 1030575 · last filed 2026-07-07
JEAN FRANCOIS FORMELA is a corporate insider who has filed 58 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $1.5M of KRRO on Jul 7, 2026. Across all open-market trades the lifetime net is −$229.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $12.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$12.40M
10
58
-$229.01M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRRO | Director | 706,556 | $13.25 | $9.36M | -$4.04M | 7 | 2026-07-07 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 241,801 | $17.16 | $4.15M | $1.61M | 6 | 2024-06-10 |
| NTLA | Director | 45,416 | $11.94 | $542.3K | -$155.43M | 20 | 2022-06-16 |
| Translate Bio, Inc. (TBIO) Delisted | Director | 0 | $0.00 | $0 | -$82.92M | 7 | 2021-09-14 |
| SPRO | Director | 1,979,557 | $1.26 | $2.49M | $6.00M | 6 | 2021-08-18 |
| Zyla Life Sciences (EGLT) Delisted | Director | 1,696,852 | — | — | $500.0K | 1 | 2014-02-12 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | 174 | $28.80 | $5.0K | -$1.06M | 5 | 2012-10-24 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | Director | 3,688,294 | $116.30 | $428.95M | $6.33M | 2 | 2012-03-06 |
| ACHILLION PHARMACEUTICALS INC (TPTX) Delisted | Director | — | $76.01 | — | $0 | 1 | 2007-12-18 |
| SGX PHARMACEUTICALS, INC. (SGXP) Delisted | Director | — | — | — | $0 | 2 | 2007-07-18 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-07 | KRRO | Sell (S) | −110,023 | -$1.54M | EDGAR |
| 2026-06-24 | KRRO | Sell (S) | −171,405 | -$2.46M | EDGAR |
| 2026-06-11 | KRRO | Grant (A) | — | $0 | EDGAR |
| 2026-06-01 | KRRO | Sell (S) | −2,860 | -$39.9K | EDGAR |
| 2025-06-12 | KRRO | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | KRRO | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-23 | KRRO | Grant (A) | +17,857 | $1000.0K | EDGAR |
| 2023-11-07 | — | Grant (A) | +1,119,292 | $0 | |
| 2023-06-13 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.